Mr. David Gordon reports
PHARMACIELO ENTERS STRATEGIC ALLIANCE TO PROVIDE PRE-TESTED AND INSURED PRODUCT TO CUSTOMERS IN THE U.S. MARKET
Pharmacielo Ltd. has entered into a strategic alliance with United States-based AssuredTrans Inc., an independent provider of cannabinoid extract testing, verification and insurance.
The alliance between AssuredTrans and Pharmacielo provides U.S. cannabidiol (CBD) buyers a value proposition that guarantees independent product quality assurance, reduced supply chain costs and customized product specifications for multiple manufacturing needs.
"At AssuredTrans, the success of our business is based on our ability to validate and verify the specifications and quality of third party products and provide product insurance to bulk purchasers in the rapidly emerging CBD extract marketplace," said
Jeremy Applen, chief operating officer of AssuredTrans. "Given the product quality we have already seen from Pharmacielo and its capability to continue producing at the specifications in demand from global buyers, we are excited to align our companies to meet the needs of U.S. customers. The market is expanding every day and we are confident that our solution, matched with Pharmacielo's extensive product range, will enable us to develop meaningful relationships with established product manufacturers as they look to add CBD to their product ranges."
AssuredTrans's patent-pending ecosystem ensures and insures both product and material specifications, protecting both the manufacturer and the supplier, a very unique solution in the current market. This proprietary system mitigates the financial and material risk associated with purchasing raw ingredients such as CBD extracts, giving large manufacturers the peace of mind and ability to produce at scale. AssuredTrans is partnered with a leading international specialist insurance provider, an 800-laboratory testing service, and customer-directed audit provision through an established logistic audit and certification firm with global offices in over 70 countries, including Colombia.
"In speaking with customers and prospects around the world and most recently in the U.S., including large established health product manufacturers, there is a growing need to provide independent laboratory analysis in confirmation of product quality," said Henning von Koss, chief executive officer
of Pharmacielo. "Through this alliance, we now have the ability to offer independent product verification, customized guaranteed specification and insurance to U.S. bulk purchasers of our extracts. Providing these key items up front gives potential customers immediate confidence in our product quality, as well as financial assurance as they look to enter into sales agreements with Pharmacielo."
"It is important to keep in mind that, despite the enormous progress that has been made, the medicinal cannabis industry is still in its formative stage. There is now an impressive level of public acceptance of the medical and health-related benefits that can be derived from the cannabis plant, but this opportunity must not be taken for granted," said former congressman Dana Rohrabacher. "By adhering to the highest global standards and enabling third party validation of its products, Pharmacielo is facilitating the development of public trust in this new industry and fostering an even greater understanding of this new and effective way to combat pain and inflammation, among other health issues. By demonstrating a serious commitment to the growth and long-term success of a global cannabis market, Pharmacielo is slamming the door on the industry's past and leading it into a new era of professional management of the production, processing and commercialization of this exciting new health-related product."
As Pharmacielo recently announced a significant expansion of its extract product range, the provision of independent laboratory analysis and insurance of its products will be available to support U.S. market entries beginning in 2021 and beyond. Individual product profiles and pricing, as well as referrals to the independent AssuredTrans services, are available through
the company's website.
The export of Pharmacielo products into the United States is subject to the approval of the TSX Venture Exchange.
About Pharmacielo Ltd.
Pharmacielo is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. Pharmacielo's principal and wholly owned subsidiary is Pharmacielo Colombia Holdings SAS, headquartered at its cultivation and processing centre located in Rionegro, Colombia.
The board of directors and executive team of Pharmacielo comprise a diversely talented group of international business executives and specialists with relevant and varied expertise. Pharmacielo recognized the significant role that Colombia's ideal location plays in building a sustainable business in the medical cannabis industry and the company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.